Biocurcumin as Radiosensitiser for Cervical Cancer Study (BRACES): A Double-Blind Randomised Placebo-Controlled Trial

Table 3

Molecular marker baseline level before and after radiation.

Variable	Total subject (power)	BCM-95 (n)	Placebo (n)	value per protocol	value ITT
Pre-radiation				0.53	0.16
MDA (nmol/mg protein)	100 (100%)	50	50
Min–max	16 × x1016 × 10^−6 – 0.36	16 × x1016 × 10^−6 – 0.27	11 × x1011 × 10^−4 – 0.36
Mean^+ (SD)	−3.1 (1.09)	−3.2 (1.37)	−3.0 (0.73)
Post-radiation				0.52	0.18
MDA (nmol/mg protein)	56 (15%)	26	30
Min–max	0.01–0.24	0.01–0.24	0.01–0.23
Mean^+ (SD)	−2.6 (0.67)	−2.5 (0.69)	−2.6 (0.65)
Ddelta MDA (%)	54 (95.6%)	25	29	0.43	0.15
Min–max	−83.2–1658.32	−83.2–764.0	−70.38–1658.32
Mean^+ (SD)	−9.9 (30.5)	−13.4 (35.6)	−6.9 (25.5)
Pre-radiation				0.98	0.92
NF-κB (mcg/mg pprotein)	101 (26.4%)	51	50
Min–max	32 × 10^−5 – 1.26	32 × 10^−5 – 1.05	65 × 10^−5 – 1.26
Mean^+ (SD)	−2.6 (1.93)	−2.6 (2.04)	−2.6 (1.83)
Post-radiation				0.018	0.42
NF-κB (mcg/mg protein)	56 (11.7%)	26	30
Min–max	85 × 10^−4–1.19	0.008–1.19	0.009–0.90
Mean^+ (SD)	−2.9 (1.38)	−2.4 (1.44)	−3.3 (1.22)
Delta NF-κB (%)	54 (100%)	25	29	0.10	0.92
Min–max	−98.45–119687.1	−98.45–119687.1	−96.8–3227.8
Mean^+ (SD)	−61.6 (924.5)	−283.3 (1227.6)	129.4 (494.2)
Pre-radiation				0.01	0.61
Apoptotic index (%)	40 (17%)	21	19
Min–max	3.6–75.8	4.04–75.8	3.6–58.86
Mean^+ (SD)	3.0 (0.08)	3.2 (0.79)	2.6 (0.72)
Post-radiation				0.04	0.91
Apoptotic index (%)	40 (98.9%)	21	19
Min–max	0.87–94.41	5.81–94.41	0.87–36.12
Mean^+ (SD)	3.01 (0.92)	3.3 (0.82)	2.6 (0.86)
Delta apoptotic index (%)				0.68	0.70
Index (%)	40 (92.3%)	21	19
Min–max	−2293.1–95.2	−494.6–95.2	−2293.1–75.3
Mean^+ (SD)	11.6 (59.8)	14.9 (63.3)	7.9 (57.2)

⁺Mean value was transformed to log-mean for statistical analysis. Delta is postradiation result − preradiation result.